Bilateral gene therapy in children with autosomal recessive deafness 9: single-arm trial results
Authors:
Top Cited Papers
Open Access
- 5 June 2024
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 30 (7) , 1898-1904
Abstract
Gene therapy is a promising approach for hereditary deafness. We recently showed that unilateral AAV1-hOTOF gene therapy with dual adeno-associated virus (AAV) serotype 1 carrying human OTOF transgene is safe and associated with functional improvements in patients with autosomal recessive deafness 9 (DFNB9). The protocol was subsequently amended and approved to allow bilateral gene therapy administration. Here we report an interim analysis of the single-arm trial investigating the safety and efficacy of binaural therapy in five pediatric patients with DFNB9. The primary endpoint was dose-limiting toxicity at 6 weeks, and the secondary endpoint included safety (adverse events) and efficacy (auditory function and speech perception). No dose-limiting toxicity or serious adverse event occurred. A total of 36 adverse events occurred. The most common adverse events were increased lymphocyte counts (6 out of 36) and increased cholesterol levels (6 out of 36). All patients had bilateral hearing restoration. The average auditory brainstem response threshold in the right (left) ear was >95 dB (>95 dB) in all patients at baseline, and the average auditory brainstem response threshold in the right (left) ear was restored to 58 dB (58 dB) in patient 1, 75 dB (85 dB) in patient 2, 55 dB (50 dB) in patient 3 at 26 weeks, and 75 dB (78 dB) in patient 4 and 63 dB (63 dB) in patient 5 at 13 weeks. The speech perception and the capability of sound source localization were restored in all five patients. These results provide preliminary insights on the safety and efficacy of binaural AAV gene therapy for hereditary deafness. The trial is ongoing with longer follow-up to confirm the safety and efficacy findings. Chinese Clinical Trial Registry registration: ChiCTR2200063181.Keywords
Funding Information
- Ministry of Science and Technology of the People’s Republic of China (2020YFA0908201, 2023YFC2508400, 2021YFA1101302)
- National Natural Science Foundation of China (82225014 and 82171148, 82192864)
- Science and Technology Commission of Shanghai Municipality (21S11905100 and 23J31900100)
- Shanghai Municipal Education Commission (2023ZKZD12)
- Fudan University (yg2022-23)
- Funder: MEE. Grant: the Ines and Fredrick Yeatts Fund.
This publication has 32 references indexed in Scilit:
- Comparison of Speech Recognition and Localization Performance in Bilateral and Unilateral Cochlear Implant Users Matched on Duration of Deafness and Age at ImplantationEar & Hearing, 2008
- A multicenter study on the prevalence and spectrum of mutations in the otoferlin gene (OTOF) in subjects with nonsyndromic hearing impairment and auditory neuropathyHuman Mutation, 2008
- Otoferlin, Defective in a Human Deafness Form, Is Essential for Exocytosis at the Auditory Ribbon SynapseCell, 2006
- Newborn Hearing Screening — A Silent RevolutionNew England Journal of Medicine, 2006
- Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune responseNature Medicine, 2006
- A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic form of deafnessNature Genetics, 1999
- Categories of Auditory Performance: Inter-User ReliabilityBritish Journal of Audiology, 1998
- Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministrationJournal of Virology, 1997
- Evaluation of the Speech Intelligibility Rating (SIR) Test for Hearing Aid ComparisonsJournal of Speech, Language, and Hearing Research, 1992
- Evaluating meaningful auditory integration in profoundly hearing-impaired children.1991